BioWorld Asia

May 25, 2005

Merck Licenses BioXell's TREM Receptor Programs For $150M

BioXell SpA could earn up to $150 million in milestone payments from Merck & Co. Inc., which has gained exclusive commercialization rights to BioXell's preclinical TREM (Triggering Receptors Expressed on Myeloid Cells) programs. (BioWorld International) Read More

Oxagen Brings In $59.8M; U.S. Firm As Lead Investor

South Koreans Report Step Forward In Cloning, Again

ProStrakan Wants £50M IPO In Tough UK Public Market

Actelion's Palurosan Fails In Diabetic Nephropathy

Active Biotech Bringing In SEK168M In Rights Offering

Moving Fast, Astex Cleared For Clinical Trial Of AT 7519

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Illustration of red and white blood cells in an artery

Case report links APOLD1 variant to vascular-type bleeding disorder

BioWorld Science

Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...